WCLC 2025 - Posters & ePosters-EP.14.21 Real-World Clinical Outcomes of Patients With Masaoka Stage Iv Thymic Carcinoma Treated With Carboplatin and Paclitaxel

EP.14.21 Real-World Clinical Outcomes of Patients With Masaoka Stage Iv Thymic Carcinoma Treated With Carboplatin and Paclitaxel

Back to course

Pdf Summary

This retrospective study evaluated real-world clinical outcomes of patients with Masaoka stage IV thymic carcinoma treated with first-line carboplatin and paclitaxel (CP) at Shizuoka Cancer Center from September 2002 to August 2024. Out of 107 thymic carcinoma patients identified, after excluding neuroendocrine tumors and earlier-stage disease, 58 stage IV patients were selected. Among them, 37 received first-line chemotherapy, with 30 treated specifically with the CP regimen. The study focused on assessing progression-free survival (PFS), overall survival (OS), and outcomes with second-line therapies post-CP treatment.<br /><br />Results showed a median PFS of 5.8 months (95% CI: 4.8–8.3) and a median OS of 28.2 months (95% CI: 22.3–63.5) for the CP group, consistent with outcomes reported in previous phase II trials despite limited treatment options. Disease progression occurred in 86.7% of CP-treated patients, but a high proportion (92%) received second-line chemotherapy after relapse. An analysis of second-line regimens—primarily lenvatinib, amrubicin, and S-1—revealed no significant differences in PFS or OS among these treatments (PFS p=0.20, OS p=0.35). Median PFS and OS for second-line therapies were approximately 7.2 and 18.8 months, respectively.<br /><br />The relatively prolonged OS compared to PFS suggests that first-line CP enables effective transition to subsequent therapies, which may be crucial for extending survival. Differences in OS compared to earlier studies might relate to the approval of newer agents like lenvatinib during the study period. Overall, the study supports the efficacy of CP chemotherapy in advanced thymic carcinoma in routine clinical settings, supporting its continued use as first-line treatment and highlighting the importance of second-line options to improve outcomes.

Asset Subtitle

Mikako Nakamura

Meta Tag

Speaker Mikako Nakamura

Topic Mesothelioma, Thymoma, and Other Thoracic Tumors

Keywords

thymic carcinoma

Masaoka stage IV

carboplatin

paclitaxel

first-line chemotherapy

progression-free survival

overall survival

second-line therapy

lenvatinib

amrubicin